Hematolymphoid
Screening Panel

CAP/CLIA accredited (US)ISO certified (EU and Asia)

Multiparametric Flow Cytometry
Clinical Information

Biomarkers in the Screening Panel

The 10-color Hematolymphoid Screening Panel provides
a comprehensive approach for evaluating bone marrow andperipheral blood samples for the presence or absence ofhematolymphoid malignancies. The panel characterizes andidentifies all major white blood cell lineages and identifies all
major types of hematopoietic neoplasia. Biomarker selection
follows the 2006 Bethesda Consensus1 for immunophenotypic
analysis of hematolymphoid neoplasia with additions chosen
by our internal hematopathologist based on recent literatureincluding the 2017 WHO Classification of Tumoursof Haematopoietic and Lymphoid Tissues.2-8This panel not only enables evaluation of patients withhematological malignancies, but provides a wide array ofapplications due to its comprehensive biomarker selection.

CD2

CD3

CD4

CD5

CD7

CD8

CD10

CD11b

CD13

CD14

CD15

CD16

CD19

CD20

CD23

CD33

CD34

CD38

CD45

CD56

CD57

CD64

CD71

CD117

CD123

HLA-DRKappa

LambdaTCR Gamma/Delta

Key Points

Indications for Testing
Classifying Acute Leukemia10-color Flow Panel

Diagnosing and Classifying B-cell Disorders

Global Standardized Testing through LabPMM Network

Evaluating T-cell and NK disorders

Flow and NGS Testing Available

Evaluating Plasma Cell Dyscrasias

Accurate Results Comparisons - No Sample Splitting
2006 Bethesda Consensus and 2017 WHO Classification
Guidance

Interpretation

Turnaround Time

Specimen Requirements

Shipping Conditions

Storage Conditions

An interpretive reportwill be issued for theinterrogated sample
indicating presence/
absence of normal andabnormal cell populations
and their associatedimmunophenotypic profile.

24 - 48 hours

2-4 mL of bone marrow or
peripheral blood in EDTAor Sodium Heparin

Ambient or Cool

2-8 °C up to 7 days

Do not freeze

References
1. BL Wood et al., Cytometry B Clin Cytom. 72:S14-S22 (2007). 2. FE Craig et al., Blood. 111(8):3941-67 (2008). 3. BL Wood. Arch Pathol Lab Med. 130:680-90 (2006) 4. SH Swerdlow et al., WHO
Classification of Tumours, Revised 4th Edition, Volume 2 (2017) 5. CLSI H43: Clinical Flow Cytometric Analysis of Neoplastic Hematolymphoid Cells, 2nd Edition 6. JJ Van Dongen et al., Leukemia.
26(9):1908-75 (2012). 7. A Porwit and A Rajab. Int. Jnl. Lab. Hem., 37:133-143 (2015). 8. Sheikholeslami et al., Methods in Molecular Biology. 378. 53-63. 10.1007/978-1-59745-323-3_4 (2007).

San Diego, USA | Munich, DE | Kawasaki, JP | Shanghai, CN
M-0038 Rev03 | June 2024

Case of Acute Myeloid Leukemia (AML)

a.

b.

c.

d.

e.

f.

Fig. 1 Representative plots from a case of acute myeloid leukemia (HLADR positive) with aberrant lymphoid antigen expression. Peripheral blood was used for flow
cytometry immunophenotype screening for leukemia and lymphoma. Expanded population of aberrant myeloid blasts were identified in support of the final AML
diagnosis. a. Gating scheme based on CD45 expression and side scatter properties to help separate lymphoid (blue), granulocytes (green), monocytes (gray), blasts/precursors (red) and debris (black) and other cells (yellow) and shows expanded population of blasts/precursors b. Blasts co-express both CD34 and CD117 (progenitor/immaturity markers) c. HLADR is expressed in a subset of blasts d. CD13 is expressed in a subset of blasts e. CD56 is expressed in subset of blasts (aberrant lymphoidantigen expression by myeloid blasts) f. Blasts express CD7 (aberrant lymphoid antigen expression by myeloid blasts)

Case of Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL)

a.

b.

c.

d.

e.

f.

Fig. 2 Representative plots from a case of CLL/SLL.. Peripheral blood was used for a flow cytometry immunophenotype screen for leukemia and lymphoma.
CD5 co-expressing lambda monoclonal mature B-cell population was identified: a total of 55% of total cells displayed a CLL/SLL immunophenotype. a. Gating scheme
based on CD45 expression and side scatter properties to help separate lymphoid (blue), granulocytes (green), monocytes (gray), blasts/precursors (red) and debris (black)and other cells (yellow) and shows expanded population of lymphocytes b. Increased B lymphocytes (91%) which coexpress both CD19 (bright) and CD20 (dimmer)
c. B-cells coexpress T-cell antigen CD5 with CD19 (aberrant expression in B-cells, characteristic of CLL, Mantle cell lymphoma, rarely in other B-cell neoplasia) d. Significantnumber of B-cells coexpress CD23 with CD19 (Common with CLL/SLL opposed to Mantle cell lymphoma ) e. CD19 VS. kappa: Kappa negative in neoplastic B-cells
f. CD19 VS. Lambda: Lambda positive/ clonality in neoplastic B-cells
Some hematopoietic neoplasms do not show immunophenotypic abnormalities, and may not be detected by flow cytometry. Hence, results should be interpreted in context of morphology, clinicalinformation, and other necessary ancillary tests (such as molecular genetic testing etc.) for a definitive diagnosis. Figures are for illustration purposes only.

invivoscribe.com

Tel +1 858.224.6600 | Fax +1 858.224.6601 | inquiry@invivoscribe.com